These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24133212)

  • 1. A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells.
    Binici J; Hartmann J; Herrmann J; Schreiber C; Beyer S; Güler G; Vogel V; Tumulka F; Abele R; Mäntele W; Koch J
    J Biol Chem; 2013 Nov; 288(48):34295-303. PubMed ID: 24133212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
    Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.
    Herrmann J; Berberich H; Hartmann J; Beyer S; Davies K; Koch J
    J Biol Chem; 2014 Jan; 289(2):765-77. PubMed ID: 24275655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAG-6, a jack of all trades in health and disease.
    Binici J; Koch J
    Cell Mol Life Sci; 2014 May; 71(10):1829-37. PubMed ID: 24305946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.
    Pogge von Strandmann E; Simhadri VR; von Tresckow B; Sasse S; Reiners KS; Hansen HP; Rothe A; Böll B; Simhadri VL; Borchmann P; McKinnon PJ; Hallek M; Engert A
    Immunity; 2007 Dec; 27(6):965-74. PubMed ID: 18055229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors.
    Kaifu T; Escalière B; Gastinel LN; Vivier E; Baratin M
    Cell Mol Life Sci; 2011 Nov; 68(21):3531-9. PubMed ID: 21877119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Important role for NKp30 in synapse formation and activation of NK cells.
    Wang H; Zheng X; Wei H; Tian Z; Sun R
    Immunol Invest; 2012; 41(4):367-81. PubMed ID: 22221078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
    Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding.
    Hartmann J; Tran TV; Kaudeer J; Oberle K; Herrmann J; Quagliano I; Abel T; Cohnen A; Gatterdam V; Jacobs A; Wollscheid B; Tampé R; Watzl C; Diefenbach A; Koch J
    J Biol Chem; 2012 Sep; 287(37):31527-39. PubMed ID: 22807449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin.
    Jarahian M; Fiedler M; Cohnen A; Djandji D; Hämmerling GJ; Gati C; Cerwenka A; Turner PC; Moyer RW; Watzl C; Hengel H; Momburg F
    PLoS Pathog; 2011 Aug; 7(8):e1002195. PubMed ID: 21901096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.
    Wang W; Guo H; Geng J; Zheng X; Wei H; Sun R; Tian Z
    J Biol Chem; 2014 Nov; 289(48):33311-9. PubMed ID: 25315772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection.
    Koch J; Steinle A; Watzl C; Mandelboim O
    Trends Immunol; 2013 Apr; 34(4):182-91. PubMed ID: 23414611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Natural Cytotoxicity Receptors in Health and Disease.
    Barrow AD; Martin CJ; Colonna M
    Front Immunol; 2019; 10():909. PubMed ID: 31134055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.
    Queiroz GAN; Mascarenhas REM; Vieillard V; Andrade RL; Galvão-Castro B; Grassi MFR
    BMC Infect Dis; 2019 May; 19(1):433. PubMed ID: 31101076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET Imaging of the Natural Killer Cell Activation Receptor NKp30.
    Shaffer TM; Aalipour A; Schürch CM; Gambhir SS
    J Nucl Med; 2020 Sep; 61(9):1348-1354. PubMed ID: 32532927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression.
    Kim N; Yi E; Lee E; Park HJ; Kim HS
    Front Immunol; 2024; 15():1388018. PubMed ID: 38698855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
    Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
    J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
    Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconstitution of a ligand-binding competent murine NKp30 receptor.
    Memmer S; Weil S; Koch J
    Immunogenetics; 2018 Mar; 70(3):185-194. PubMed ID: 28782088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.